{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-3CJVE8PO/96572821-fece-407b-9d29-424387e8fb99/HTML","dcterms:extent":"50 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-3CJVE8PO/e55e5661-38fd-413b-bf11-4dd91490f511/PDF","dcterms:extent":"125 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-3CJVE8PO/e4527dbe-f20b-4877-a0fa-6f95fc1f2860/TEXT","dcterms:extent":"18 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-3CJVE8PO","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2008","dc:creator":["Čeh, Marija","Fikfak, Nataša","Glaser, Marjana","Grat, Mateja","Grmek-Zemljič, Tatjana","Pajič, Tadej","Petric, Vlasta","Preložnik-Zupan, Irena","Umek Bricman, Irena"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"5 strani"},{"@xml:lang":"sl","#text":"letnik:77"},{"@xml:lang":"sl","#text":"str. I-51-I-55"}],"dc:identifier":["ISSN:1318-0347","COBISSID:2916927","URN:URN:NBN:SI:doc-3CJVE8PO"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Epidemiologija"},{"@xml:lang":"sl","#text":"epidemiologija Levkemija, mieloična, kronična"},{"@xml:lang":"en","#text":"epidemiology"},{"@xml:lang":"sl","#text":"hematologija"},{"@xml:lang":"en","#text":"Leukemia, Myeloid, Chronic-Phase"},{"@xml:lang":"sl","#text":"levkemija"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"Zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Epidemiološki podatki bolnikov s kronično mieloično levkemijo v Sloveniji (2002-2007)| Chronic myeloid leukaemia: epidemiology data (2002-2007)|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Chronic myeloid leukaemia (CML) is a rare clonal neoplastic disease of hematopoietic stem cells. Epidemiology data of CML patients in Slovenia are presented. Methods. Data about all new patients with CML in the period from 2002 to 2007 were obtained from all Slovenian hospitals with haematological department. Results. 90 patients were studied during the period of 6 years. The incidence was 0.75/100,000 on average. 14 patients (15 %) died. Incidence in male population was 4 % higher as in female population. The patient population (average age 50.6 in males and 59.1 in females at the diagnosis of CML, respectively) was distributed also according to Slovenian statistical regions. The majority of patients was identified in the chronic phase of disease (83 %), being treated in recent years with imatinib (up to 85 % in 2007)"},{"@xml:lang":"sl","#text":"Izhodišča. Kronična mieloična levkemija (KML) je redka klonska neoplazma hematopoetičnih matičnih celic. Predstavljamo epidemiološke podatke slovenskih bolnikov. Metode. Podatke o novih bolnikih s KML smo zbirali v vseh slovenskih bolnišnicah, ki imajo specializirane oddelke za hematologijo, za obdobje 2002 do 2007. Rezultati. Skupno smo odkrili 90 bolnikov v šestih letih. Incidenca je bila v povprečju 0,75/100.000. Umrlo je 14 (15 %) bolnikov. Obolevnost moških je za 4 % večja od žensk. Povprečna starost moških ob ugotovitvi bolezni je bila 50,6 let in žensk 59,1 let. Bolnike smo porazdelili po statističnih regijah Slovenije. Večino bolnikov odkrijemo v kroničnem obdobju bolezni (83 %). V zadnjih letih jih zdravimo v največjem odstotku z imatinibom (do 85 %). Zaključki. Ugotavljamo manjso incidenco obolevnosti za KML v Sloveniji, tudi povprečna starost bolnikov ob ugotovitvi je nižja, kot jo opisujejo v literaturi. Bolezen odkrijemo pri večini bolnikov v zgodnjem kroničnem obdobju. Zdravimo jih po najsodobnejših priporočilih"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-3CJVE8PO","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-3CJVE8PO"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-3CJVE8PO/e55e5661-38fd-413b-bf11-4dd91490f511/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-3CJVE8PO/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-3CJVE8PO"}}}}